Donepezil helps patients with severe Alzheimer's diseaseBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39290.503900.DB (Published 02 August 2007) Cite this as: BMJ 2007;335:226
- Janice Hopkins Tanne
- New York
Patients with severe Alzheimer's disease who are living at home with family care givers and are treated with donepezil stabilise or decline more slowly than patients given placebo, according to a multinational, randomised, placebo controlled trial published in Neurology (2007;69:459-69).
Donepezil was approved by the US Food and Drug Administration last year for the treatment of severe Alzheimer's disease as well as mild to moderate forms. The Canadian authorities approved its use for severe forms of the disease in June 2007.
Sandra Black, of the University of Toronto and lead author of the paper, said that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial